{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:10:37Z","timestamp":1769170237576,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and\/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5\u20139) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5\u20136). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D<jats:sub>3<\/jats:sub> should not be used in COVID-19 routine care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-021-01645-2","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T14:04:42Z","timestamp":1625580282000},"page":"93-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Key summary of German national treatment guidance for hospitalized COVID-19 patients"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2989-0436","authenticated-orcid":false,"given":"Jakob J.","family":"Malin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-5367","authenticated-orcid":false,"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-1910","authenticated-orcid":false,"given":"Uwe","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-7356","authenticated-orcid":false,"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0172","authenticated-orcid":false,"given":"Steffen","family":"Weber-Carstens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-7050","authenticated-orcid":false,"given":"Gereon","family":"Sch\u00e4lte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-4287","authenticated-orcid":false,"given":"Petra","family":"Gastmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-814X","authenticated-orcid":false,"given":"Martin","family":"Wepler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2514-1304","authenticated-orcid":false,"given":"Michael","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-5000","authenticated-orcid":false,"given":"Michael","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-1401","authenticated-orcid":false,"given":"Klaus F.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-2455","authenticated-orcid":false,"given":"Florian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-8931","authenticated-orcid":false,"given":"Bernd W.","family":"B\u00f6ttiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-8381","authenticated-orcid":false,"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-7866","authenticated-orcid":false,"given":"Alexander","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-7256","authenticated-orcid":false,"given":"Peter","family":"Berlit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-1182","authenticated-orcid":false,"given":"Wiebke","family":"Nehls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2117-0944","authenticated-orcid":false,"given":"Sven","family":"Laudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-0429","authenticated-orcid":false,"given":"Miriam","family":"Stegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-6192","authenticated-orcid":false,"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-7391","authenticated-orcid":false,"given":"Monika","family":"Nothacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-4234","authenticated-orcid":false,"given":"Gernot","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-2849","authenticated-orcid":false,"given":"Christian","family":"Karagiannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8391-3988","authenticated-orcid":false,"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"1645_CR1","unstructured":"World Health Organization (WHO) Handbook for guideline development 2nd edition. 2021. https:\/\/www.who.int\/publications\/guidelines\/handbook_2nd_ed.pdf?ua=1. (Accessed 18 May 2021)."},{"key":"1645_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12961-018-0320-2","volume":"16","author":"J Moberg","year":"2018","unstructured":"Moberg J, Oxman AD, Rosenbaum S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018;16:45. https:\/\/doi.org\/10.1186\/s12961-018-0320-2.","journal-title":"Health Res Policy Syst"},{"key":"1645_CR3","unstructured":"AWMF. S3 Leitlinie Empfehlungen zur station\u00e4ren Therapie von Patienten mit COVID-19 (Registernummer 113-001). Assoc Scient Med Soc Germany (AWMF). https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/113-001.html. (Accessed 10 May 2021)."},{"key":"1645_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00063-020-00674-3","volume":"115","author":"S Kluge","year":"2020","unstructured":"Kluge S, Janssens U, Welte T, et al. Recommendations for critically ill patients with COVID-19. Med Klin Intensivmed Notfmed. 2020;115:175\u20137. https:\/\/doi.org\/10.1007\/s00063-020-00674-3.","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"1645_CR5","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0110","author":"S Kluge","year":"2021","unstructured":"Kluge S, Janssens U, Spinner CD, et al. Clinical practice guideline: recommendations on inpatient treatment of patients with COVID-19. Dtsch Arztebl Int. 2021. https:\/\/doi.org\/10.3238\/arztebl.m2021.0110.","journal-title":"Dtsch Arztebl Int"},{"key":"1645_CR6","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"World Health Organization (WHO) - Working Group on the Clinical_Characterisation and Management of Covid-infection","year":"2020","unstructured":"World Health Organization (WHO) - Working Group on the Clinical_Characterisation and Management of Covid-infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7.","journal-title":"Lancet Infect Dis"},{"key":"1645_CR7","unstructured":"MagicApp. MAGIC Foundation. https:\/\/app.magicapp.org. (Accessed 20 May 2021)."},{"key":"1645_CR8","unstructured":"Association of the Scientific Medical Societies in Germany (AWMF). AWMF guidance manual and rules for guideline development, 2nd Edition 2020. https:\/\/www.awmf.org\/leitlinien\/awmf-regelwerk\/awmf-publikationen-zu-leitlinien\/leitlinien-manual.html. (Accessed 20 May 2021)."},{"key":"1645_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"key":"1645_CR10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2020.17021","volume":"324","author":"BM Tomazini","year":"2020","unstructured":"Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307\u201316. https:\/\/doi.org\/10.1001\/jama.2020.17021.","journal-title":"JAMA"},{"key":"1645_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02808-2020","author":"M Edalatifard","year":"2020","unstructured":"Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.02808-2020.","journal-title":"Eur Respir J"},{"key":"1645_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2020.16761","volume":"324","author":"PF Dequin","year":"2020","unstructured":"Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298\u2013306. https:\/\/doi.org\/10.1001\/jama.2020.16761.","journal-title":"JAMA"},{"key":"1645_CR13","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","volume":"72","author":"CMP Jeronimo","year":"2021","unstructured":"Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb Placebo-controlled Trial. Clin Infect Dis. 2021;72:e373\u201381. https:\/\/doi.org\/10.1093\/cid\/ciaa1177.","journal-title":"Clin Infect Dis"},{"key":"1645_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317\u201329. https:\/\/doi.org\/10.1001\/jama.2020.17022.","journal-title":"JAMA"},{"key":"1645_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","volume":"181","author":"O Hermine","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32\u201340. https:\/\/doi.org\/10.1001\/jamainternmed.2020.6820.","journal-title":"JAMA Intern Med"},{"key":"1645_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2030340.","journal-title":"N Engl J Med"},{"key":"1645_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","volume":"181","author":"C Salvarani","year":"2021","unstructured":"Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24\u201331. https:\/\/doi.org\/10.1001\/jamainternmed.2020.6615.","journal-title":"JAMA Intern Med"},{"key":"1645_CR18","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2028836.","journal-title":"N Engl J Med"},{"key":"1645_CR19","doi-asserted-by":"publisher","first-page":"n84","DOI":"10.1136\/bmj.n84","volume":"372","author":"VC Veiga","year":"2021","unstructured":"Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84. https:\/\/doi.org\/10.1136\/bmj.n84.","journal-title":"BMJ"},{"key":"1645_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384:1491\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2100433.","journal-title":"N Engl J Med"},{"key":"1645_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2028700.","journal-title":"N Engl J Med"},{"key":"1645_CR22","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"W Peter","year":"2021","unstructured":"Peter W, Horby MC, Staplin N, Spata E, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0.","journal-title":"Lancet"},{"key":"1645_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","volume":"9","author":"AS Soin","year":"2021","unstructured":"Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9:511\u201321. https:\/\/doi.org\/10.1016\/S2213-2600(21)00081-3.","journal-title":"Lancet Respir Med"},{"key":"1645_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"issue":"6","key":"1645_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184.","journal-title":"N Engl J Med"},{"key":"1645_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.16349.","journal-title":"JAMA"},{"key":"1645_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/s0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569\u201378. https:\/\/doi.org\/10.1016\/s0140-6736(20)31022-9.","journal-title":"Lancet"},{"key":"1645_CR28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301","author":"JD Goldman","year":"2020","unstructured":"Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2015301.","journal-title":"N Engl J Med"},{"key":"1645_CR29","unstructured":"World Health Organization (WHO). COVID-19 Clinical management Living guidance 2021. https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1328457\/retrieve. (Accessed 20 May 2021)."},{"key":"1645_CR30","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013105","author":"A Simonis","year":"2020","unstructured":"Simonis A, Theobald SJ, F\u00e4tkenheuer G, et al. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2020. https:\/\/doi.org\/10.15252\/emmm.202013105.","journal-title":"EMBO Mol Med"},{"key":"1645_CR31","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460\u201370. https:\/\/doi.org\/10.1001\/jama.2020.10044.","journal-title":"JAMA"},{"key":"1645_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939","volume":"371","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371: m3939. https:\/\/doi.org\/10.1136\/bmj.m3939.","journal-title":"BMJ"},{"key":"1645_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2031304.","journal-title":"N Engl J Med"},{"key":"1645_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/11101849.2020.1842087","volume":"36","author":"O Hamdy Salman","year":"2020","unstructured":"Hamdy Salman O, Ail Mohamed HS. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egypt J Anaesth. 2020;36:264\u201372. https:\/\/doi.org\/10.1080\/11101849.2020.1842087.","journal-title":"Egypt J Anaesth"},{"key":"1645_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa2033130","volume":"384","author":"JD Lundgren","year":"2021","unstructured":"Lundgren JD, Grund B, Barkauskas CE, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384:905\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2033130.","journal-title":"N Engl J Med"},{"key":"1645_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2035002.","journal-title":"N Engl J Med"},{"key":"1645_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2029849.","journal-title":"N Engl J Med"},{"key":"1645_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","volume":"325","author":"RL Gottlieb","year":"2021","unstructured":"Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632\u201344. https:\/\/doi.org\/10.1001\/jama.2021.0202.","journal-title":"JAMA"},{"key":"1645_CR39","unstructured":"U.S. Food and Drug Administration (FDA). Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. www.fda.gov\/media\/145802\/download. (Accessed 12 May 2021)."},{"key":"1645_CR40","unstructured":"Association of the Scientific Medical Societies in Germany (AWMF). S3-Leitlinie prophylaxe der ven\u00f6sen thromboembolie (VTE). https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/003-001.html. (Accessed 12 May 2021)."},{"key":"1645_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/m20-2003","volume":"173","author":"D Wichmann","year":"2020","unstructured":"Wichmann D, Sperhake JP, L\u00fctgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268\u201377. https:\/\/doi.org\/10.7326\/m20-2003.","journal-title":"Ann Intern Med"},{"key":"1645_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1055\/a-1178-3551","volume":"40","author":"F Langer","year":"2020","unstructured":"Langer F, Kluge S, Klamroth R, et al. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie. 2020;40:264\u20139. https:\/\/doi.org\/10.1055\/a-1178-3551.","journal-title":"Hamostaseologie"},{"key":"1645_CR43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","volume":"332","author":"AT Cohen","year":"2006","unstructured":"Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325\u20139. https:\/\/doi.org\/10.1136\/bmj.38733.466748.7C.","journal-title":"BMJ"},{"key":"1645_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/nejm199909093411103","volume":"341","author":"MM Samama","year":"1999","unstructured":"Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999;341:793\u2013800. https:\/\/doi.org\/10.1056\/nejm199909093411103.","journal-title":"N Engl J Med"},{"key":"1645_CR45","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/01.Cir.0000138928.83266.24","volume":"110","author":"A Leizorovicz","year":"2004","unstructured":"Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874\u20139. https:\/\/doi.org\/10.1161\/01.Cir.0000138928.83266.24.","journal-title":"Circulation"},{"key":"1645_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1055\/s-0040-1721664","volume":"121","author":"R Patell","year":"2021","unstructured":"Patell R, Chiasakul T, Bauer E, et al. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost. 2021;121:76\u201385. https:\/\/doi.org\/10.1055\/s-0040-1721664.","journal-title":"Thromb Haemost"},{"key":"1645_CR47","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/jth.14888","volume":"18","author":"S Middeldorp","year":"2020","unstructured":"Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995\u20132002. https:\/\/doi.org\/10.1111\/jth.14888.","journal-title":"J Thromb Haemost"},{"key":"1645_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148\u201350. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.041.","journal-title":"Thromb Res"},{"key":"1645_CR49","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"P Sadeghipour","year":"2021","unstructured":"Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs. standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325:1620\u201330. https:\/\/doi.org\/10.1001\/jama.2021.4152.","journal-title":"JAMA"},{"key":"1645_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.13.21256846","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation in non-critically Ill patients with Covid-19. medrXiv. 2021. https:\/\/doi.org\/10.1101\/2021.05.13.21256846.","journal-title":"medrXiv"},{"key":"1645_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"E Abaleke","year":"2021","unstructured":"Abaleke E, Abbas M, Abbasi S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:605\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(21)00149-5.","journal-title":"Lancet"},{"key":"1645_CR52","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","volume":"396","author":"RHM Furtado","year":"2020","unstructured":"Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396:959\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(20)31862-6.","journal-title":"Lancet"},{"key":"1645_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019014","author":"AB Cavalcanti","year":"2020","unstructured":"Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2019014.","journal-title":"N Engl J Med"},{"key":"1645_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106143","volume":"56","author":"E Sekhavati","year":"2020","unstructured":"Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int J Antimicrob Agents. 2020;56: 106143. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106143.","journal-title":"Int J Antimicrob Agents"},{"key":"1645_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1055\/s-0043-121734","volume":"72","author":"K Dalhoff","year":"2018","unstructured":"Dalhoff K, Abele-Horn M, Andreas S, et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia - update 2017. Pneumologie. 2018;72:15\u201363. https:\/\/doi.org\/10.1055\/s-0043-121734.","journal-title":"Pneumologie"},{"key":"1645_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/s-0042-101873","volume":"70","author":"S Ewig","year":"2016","unstructured":"Ewig S, H\u00f6ffken G, Kern WV, et al. Management of adult community-acquired pneumonia and prevention - Update 2016. Pneumologie. 2016;70:151\u2013200. https:\/\/doi.org\/10.1055\/s-0042-101873.","journal-title":"Pneumologie"},{"key":"1645_CR57","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3714649.Accessed20May","author":"A Krolewiecki","year":"2021","unstructured":"Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label. Multicentre Trial. 2021. https:\/\/doi.org\/10.2139\/ssrn.3714649.Accessed20May.","journal-title":"Multicentre Trial"},{"key":"1645_CR58","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-116547\/v1","author":"C Carlos","year":"2021","unstructured":"Carlos C, Aina C, Andres Blanco-Di M, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. Res Square. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-116547\/v1.","journal-title":"Res Square"},{"key":"1645_CR59","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.05.21249310","author":"RR Ravikirti","year":"2021","unstructured":"Ravikirti RR, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 \u2013 A double blind randomized placebo-controlled trial. medrXiv. 2021. https:\/\/doi.org\/10.1101\/2021.01.05.21249310.","journal-title":"medrXiv"},{"key":"1645_CR60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","volume":"103","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214\u20136. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.191.","journal-title":"Int J Infect Dis"},{"key":"1645_CR61","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1016\/j.xphs.2020.08.024","volume":"109","author":"B Jermain","year":"2020","unstructured":"Jermain B, Hanafin PO, Cao Y, et al. Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing. J Pharm Sci. 2020;109:3574\u20138. https:\/\/doi.org\/10.1016\/j.xphs.2020.08.024.","journal-title":"J Pharm Sci"},{"key":"1645_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2020.105751","volume":"203","author":"M Entrenas Castillo","year":"2020","unstructured":"Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203: 105751. https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105751.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1645_CR63","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1056\/NEJMoa1911124","volume":"381","author":"AA Ginde","year":"2019","unstructured":"Ginde AA, Brower RG, Caterino JM, et al. Early high-dose vitamin D(3) for critically Ill, vitamin D-deficient patients. N Engl J Med. 2019;381:2529\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1911124.","journal-title":"N Engl J Med"},{"key":"1645_CR64","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2020.26848","volume":"325","author":"IH Murai","year":"2021","unstructured":"Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021;325:1053\u201360. https:\/\/doi.org\/10.1001\/jama.2020.26848.","journal-title":"JAMA"},{"key":"1645_CR65","unstructured":"Deutsche Gesellschaft f\u00fcr Ern\u00e4hrung E. V. (DGE). Zum Zusammenhang zwischen der Vitamin-D-Zufuhr bzw. dem Vitamin-D-Status und dem Risiko f\u00fcr eine SARS-CoV-2-Infektion sowie der Schwere des Verlaufs einer COVID-19-Erkrankung \u2013 ein \u00dcberblick \u00fcber die aktuelle Studienlage (Stand 11. Januar 2021). www.dge.de\/uploads\/media\/DGE_Fachinfo_VitaminD_COVID-19_Stand_Januar_2021.pdf. (Accessed 12 May 2021)."},{"key":"1645_CR66","doi-asserted-by":"publisher","first-page":"e00162","DOI":"10.1128\/cmr.00162-20","volume":"34","author":"JJ Malin","year":"2020","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V, et al. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34:e00162-e220. https:\/\/doi.org\/10.1128\/cmr.00162-20.","journal-title":"Clin Microbiol Rev"},{"key":"1645_CR67","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s15010-021-01665-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01645-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-021-01645-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01645-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T15:07:14Z","timestamp":1643641634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-021-01645-2"}},"subtitle":["Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)"],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s15010-021-01645-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s15010-021-01665-y","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s15010-021-01665-y","URL":"https:\/\/doi.org\/10.1007\/s15010-021-01665-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C. D. Spinner received consultancy fees, speaker\u2019s honoraria, and\/or reimbursement of travel expenses from Gilead Sciences, Eli Lilly, Janssen-Cilag, MSD and received consultancy fees from Molecular Partners and Formycon in the context of COVID-19. He also received research support indirectly from Apeiron, Eli Lilly, Gilead Sciences, and Janssen-Cilag. Outside this context, he received consultancy fees, speaker\u2019s honoraria, and reimbursement of travel expenses from AbbVie, Gilead Sciences, Janssen-Cilag, MSD, and ViiV Healthcare\/GSK, as well as research support (indirectly to his employer) from Gilead Sciences, GSK, Jansen-Cilag, MSD, and ViiV Healthcare. T. Welte received consultancy fees from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, GSK, Janssens, Novartis, Pfizer and Roche. He received lecture fees and travel cost support from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Berlin Chemie GSK, Infectopharm, MSD, Novartis, Pfizer, Roche and research support By DFG, BMBF, EU, WHO. S. Weber-Carstens is working in a scientific cooperation project with the company Dr\u00e4ger. F. Langer has received personal fees for lectures, advisory boards or consultancy and\/or research support from Aspen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, LEO Pharma, Pfizer, and Sanofi, outside the submitted work. M. Westhoff received lecture honoraria from Actelion, Boehringer, Novartis, L\u00f6wenstein, and research support from Bayer. M. Pfeifer received lecture fees from Astra-Zeneca, Boehringer, Chiesi, Glaxo-Smith-Kline, Novartis, and Roche. He received consulting fees from Boehringer, Chiesi, Novartis, and Roche, and travel support from Boehringer. K. F. Rabe has received consultancy fees from AstraZeneca, Boehringer, Sanofi Aventis, MSD, and Novartis. He received lecture fees and travel support from Roche, Chiesi Pharmaceuticals, Pfizer, TEVA Pharmaceuticals, Orion Cooperation, Berlin Chemie, Boehringer, AstraZeneca, MSD, Novartis, and Sanofi Aventis, research support from the German Federal Ministry of Education and Research. B. W. B\u00f6ttiger received fees for lectures from the following companies: Forum f\u00fcr medizinische Fortbildung (FomF), Baxalta Deutschland GmbH, ZOLL Medical Deutschland GmbH, C.R. Bard GmbH, GS Elektromedizinische Ger\u00e4te G. Stemple GmbH, Novartis Pharma GmbH, Philips GmbH Market DACH, Bioscience Valuation BSV GmbH. J. Weinmann-Menke received research support from GSK, DIAMED, Miltenyi Biotech, lecture fees from Astellas, Astra Zeneca, Norvartis, Bial, Roche, Chiesi, GSK, Boehringer-Ingelheim, Miltenyi, Bayer, Vifor, Fresenius. She received consultancy fees from Bayer, Bial, Boehringer-Ingelheim, Chiesi, Astra Zeneca and GSK. M. Nothacker is a guideline methodologist payed by the AWMF. G. Marx received consultancy fees and research support from Biotest, B.Braun, and Adrenomed, and lecture fees from B.Braun, Biotest, and Philips. He holds a patent for modulation of the TLR4 signaling pathway (European Patent 2855519). C. Karagiannidis has received consultancy fees from Bayer and Xenios. S. Kluge has received research support from Ambu, Daiichi Sankyo, ETView Ltd, Fisher & Paykel, Pfizer, and Xenios. He has received lecture honoraria from Astra, C.R. Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips, ZOLL. He received consultancy fees from Bayer, Fresenius, Gilead, MSD and Pfizer. J. J. Malin, U. Janssens, G. Sch\u00e4lte, P. Gastmeier, M. Wepler, F. Hoffmann, A. Kersten, P. Berlit, M. Krawczyk, W. Nehls, F. Fichtner, S. Laudi, M. Stegemann and N. Skoetz report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}